Compare · BDX vs DRIO
BDX vs DRIO
Side-by-side comparison of Becton Dickinson and Company (BDX) and DarioHealth Corp. (DRIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and DRIO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $51.45B, about 963.4x DRIO ($53.4M).
- Over the past year, BDX is up 3.4% and DRIO is down 62.6% - BDX leads by 66.0 points.
- DRIO has been more active in the news (10 items in the past 4 weeks vs 9 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 5 for DRIO).
- Company
- Becton Dickinson and Company
- DarioHealth Corp.
- Price
- $191.68-1.09%
- $5.00-5.12%
- Market cap
- $51.45B
- $53.4M
- 1M return
- +5.72%
- -27.64%
- 1Y return
- +3.42%
- -62.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 10
- Recent ratings
- 25
- 5
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
DarioHealth Corp.
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is based in New York, New York.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest DRIO
- DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs
- Director Shaked Yoav converted options into 772 shares and was granted 54,000 shares, increasing direct ownership by 167% to 87,582 units (SEC Form 4)
- Director Mcgrath Dennis M was granted 61,000 shares, increasing direct ownership by 220% to 88,737 units (SEC Form 4)
- Director Palumbo John R was granted 62,000 shares, increasing direct ownership by 1,378% to 66,500 units (SEC Form 4)
- Director Stern Adam K converted options into 20,195 shares and was granted 28,000 shares, increasing direct ownership by 94% to 57,717 units (SEC Form 4)
- Director Matheis Dennis was granted 44,000 shares, increasing direct ownership by 102% to 87,026 units (SEC Form 4)
- Chief Financial Officer Franco-Yehuda Chen was granted 95,000 shares, increasing direct ownership by 317% to 125,000 units (SEC Form 4)
- Director Karah Hila was granted 28,000 shares, increasing direct ownership by 90% to 58,965 units (SEC Form 4)
- Chief Executive Officer Raphael Erez converted options into 579 shares and was granted 297,000 shares, increasing direct ownership by 190% to 454,432 units (SEC Form 4)
- New insider Sherman Lara Ann claimed ownership of 120,000 shares (SEC Form 3)